Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Spyre Therapeutics, Inc.

Market Cap 663.81Cr 574.2Cr 529.09Cr 495.88Cr 926.21Cr 63TCr 943.15Cr 6.28TCr 2.44TCr 31TCr 2.49TCr 2.44TCr 1,06400Cr P/E ratio 2026 *
-25.4x
P/E ratio 2027 * -23.3x
Enterprise value 605.84Cr 524.05Cr 482.89Cr 452.58Cr 845.32Cr 58TCr 860.78Cr 5.73TCr 2.22TCr 28TCr 2.27TCr 2.23TCr 97TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.14%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week+4.40%
Current month+4.43%
1 month+0.43%
3 months+84.64%
6 months+121.45%
Current year+134.29%
1 week 70.89
Extreme 70.89
79.54
1 month 64.67
Extreme 64.67
79.54
Current year 28
Extreme 28
79.54
1 year 13.93
Extreme 13.9301
79.54
3 years 2.66
Extreme 2.66
79.54
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 27/11/2023
Director of Finance/CFO 49 01/09/2023
Chief Tech/Sci/R&D Officer - 27/11/2023
Director TitleAgeSince
Director/Board Member 36 27/11/2023
Director/Board Member 39 22/06/2023
Director/Board Member 36 22/06/2023
Date Insider Type Main position Quantity % Market Cap.
03/06Fiscal year

Chief Technology Officer

24,999 0.0288%
01/06Fiscal year

Chief Financial Officer

22,500 0.0259%
01/06Sell

Chief Executive Officer

-15,000 0.0173%
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%+4.40%+313.55%+2,094.57% 663.81Cr
+0.66%+10.04%+50.63%+106.81% 5.45TCr
+3.81%-2.72%+49.75%+43.89% 4.17TCr
-0.58%-2.93%-19.67%-21.80% 2.19TCr
-4.48%-8.34%+4.70%+388.21% 2.15TCr
-0.80%-15.48%+14.23%-33.78% 1.58TCr
-0.16%+5.51%+7.56%-40.44% 1.53TCr
+0.49%+2.66%+24.58%+177.48% 1.33TCr
+3.61%-0.55%+16.69% - 1.15TCr
-9.45%-12.48%-40.26%+641.01% 1.11TCr
Average -0.70%+0.34%+42.17%+372.88% 2.13TCr
Weighted average by Cap. +0.13%+1.35%+32.83%+187.08%

Financials

2026 *2027 *
Net sales - -
Net income -26Cr -22Cr -21Cr -19Cr -36Cr -2.48TCr -37Cr -245.57Cr -95Cr -1.2TCr -98Cr -95Cr -4.16TCr -30Cr -26Cr -24Cr -22Cr -42Cr -2.86TCr -43Cr -283.14Cr -109.87Cr -1.38TCr -112.44Cr -110Cr -4.8TCr
Net Debt -58Cr -50Cr -46Cr -43Cr -81Cr -5.53TCr -82Cr -548.14Cr -212.71Cr -2.67TCr -217.69Cr -212.96Cr -9.29TCr -49Cr -42Cr -39Cr -36Cr -68Cr -4.65TCr -69Cr -461.41Cr -179.05Cr -2.25TCr -183.24Cr -179.26Cr -7.82TCr
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Employees
112
Date Price Change Volume
10/26/10 76.82 $ +0.50% 3,16,741
09/26/09 76.44 $ +6.17% 15,93,140
08/26/08 72.00 $ -2.24% 10,36,035
05/26/05 73.65 $ -6.15% 14,79,793
04/26/04 78.48 $ +6.75% 11,19,156
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
76.44USD
Average target price
96.07USD
Spread / Average Target
+25.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW